

CORDINE LS

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only

Abbreviated Prescribing information for CORDINE LS [Levosalbutamol, Ambroxol Hydrochloride & Guaiphenesin Syrup]

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES:

MECHANISM OF ACTION: Activation of β_2 adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of 3',5'-cyclic adenosine monophosphate (cyclic AMP). The increase in cyclic AMP is associated with the activation of protein kinase A, which in turn, inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in muscle relaxation. Levosalbutamol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Increased cyclic AMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways. Levosalbutamol acts as a functional agonist that relaxes the airway irrespective of the spasmogen involved, thereby protecting against all Broncho constrictor challenges. Ambroxol is a mucolytic agent. Excessive Nitric oxide (NO) is associated with inflammatory and some other disturbances of airways function. NO enhances the activation of soluble guanylate cyclase and cGMP accumulation. Ambroxol has been shown to inhibit the NO-dependent activation of soluble guanylate cyclase. It is also possible that the inhibition of NO-dependent activation of soluble guanylate cyclase can suppress the excessive mucus secretion; therefore, it lowers the phlegm viscosity and improves the mucociliary transport of bronchial secretions. Guaifenesin may act as an irritant to gastric vagal receptors, and recruit efferent parasympathetic reflexes that cause glandular exocytosis of a less viscous mucus mixture. Cough may be provoked. This combination may flush tenacious, congealed mucopurulent material from obstructed small airways and lead to a temporary improvement in dyspnea or the work of breathing

INDICATIONS: It is indicated for the symptomatic relief of bronchospasm in bronchial asthma & chronic bronchitis

DOSAGE AND ADMINISTRATION: For adults: 5-10 ml thrice daily, for pediatric patients(aged 6-12 years) 5 ml thrice daily or as directed by the physician.

CONTRAINDICATION: Known hypersensitivity to any of the components of the formulation. Patients with pre-existing ischaemic heart disease or those patients with significant risk factors for ischaemic heart disease. Patients with gastric ulceration. It should not be used for threatened abortion during the first or second trimester of pregnancy. Levosalbutamol and beta-blocking drugs such as propranolol should not usually be prescribed together.

WARNINGS & PRECAUTIONS: Levosulbutamol Sulphate: Paradoxical bronchospasm, deterioration asthma, cardiovascular effects, use of anti-inflammatory agents, do not exceed the recommended dose, immediate hypersensitivity reaction, coexisting condition, hypokalemia. Ambroxol hydrochloride Care should be taken to avoid contact with the eyes and skin, and serious ingestion or inhalation Guaifenesin Caution should be exercised in the presence of severe renal or severe hepatic impairment.

DRUG INTERACTIONS: Beta-adrenergic receptor-blocking agents not only block the pulmonary effect of beta-agonists such as levosalbutamol but may also produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, use of beta-adrenergic blocking agents could be considered, although they should be administered with caution. Concomitant use with antitussive agents, e.g. codeine should be avoided, because they may inhibit cough reflex. Expectorants such as guaifenesin should not be combined with cough suppressants in the treatment of cough since the combination is illogical and patients may be exposed to unnecessary adverse effects.

ADVERSE REACTIONS: Palpitations, fine tremors of the skeletal muscles, muscle cramps, rash, urticaria, hypersensitivity, anaphylactic reactions, including anaphylactic shock; angio-oedema, pruritus and other hypersensitivity reactions, severe cutaneous adverse reactions (including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis and acute generalised exanthematous pustulosis) dysgeusia, nausea, oral and pharyngeal hypoesthesia, vomiting diarrhea, dyspepsia, abdominal pain, dry mouth, dry throat.

MARKETED BY:

TORRENT
PHARMA

Torrent Pharmaceuticals Limited.

IN/CORDINE LS /APR 2026/02/ABPI

(Additional information is available on request)